Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise

Study: Drug Therapy Improving Function in Kids with SMA Types 2 & 3

November 29, 2022 by Laurie Watanabe

A newly published study says a drug therapy for children with spinal muscular atrophy (SMA) is improving their upper-extremity function.

The study, published in Orphanet Journal of Rare Diseases in October, is called, “Improved Upper Limb Function in Non-Ambulant Children with SMA Type 2 and 3 During Nusinersen Treatment: A Prospective 3-Years SMArtCARE Registry Study.”

The SMArtCARE Registry collects data from SMA patients in Germany, Austria, and Switzerland.

The study centers on SMArtCARE registry data for children under age 18 with SMA Type 2 or 3 who have taken Nusinersen — marketed as Spinraza — and were under a 38-month follow-up period.

Spinraza is taken three times a year after four initial doses, according to its manufacturer.

Researchers studied 256 non-ambulatory pediatric patients. “Improvements in motor function were more prominent in upper limb: 32.4 percent of patients experienced clinically meaningful improvements in RULM [Revised Upper Limb Module, an assessment of upper-extremity function in patients with SMA], and 24.6 percent in the HFMSE [Hammersmith Functional Motor Scale Expanded, which assesses high-functioning SMA Type 2 and 3 patients].”

The study said 4.3 percent and 1.2 percent of patients had worsening results in HFMSE or RULM scores, respectively.

“Our results demonstrate clinically meaningful improvements or stabilization of disease progression in non-ambulant, pediatric patients with SMA under Nusinersen treatment,” the study said. “Changes were most evident in upper-limb function and were observed continuously over the follow-up period. Our data confirm clinical trial data, while providing longer follow-up, an increased number of treated patients, and a wider range of age and disease severity.”

 

Related Articles Read More >

New NIH, CMS Partnership Aims to Build ‘Data Platform’ for Research on Chronic Conditions
Despite assurances that patient privacy will be protected, some health-care stakeholders are wary about data sharing.
MaRS, Toyota Mobility Foundation Call for Startups to Join Mobility Unlimited Hub in Toronto
The program provides funding, technical and marketing support to cohort members.
Reviewing RESNA’s Evacuation Standard: Performance Requirements, Installations, Inspections … and Why They Matter
The standard is open for comment till June 23.
Briefly: ‘Stronger Together’ Podcast Launches May 13; Parkinson’s Researchers Seeking Volunteers for Scratch-and-Sniff Test
Featuring United Spinal Association, M.A.R.C. Network, and the Michael J. Fox Foundation.

GET THE FREE NEWSLETTER

Mobility Management Newsletter

Subscribe to Mobility Management's newsletter for industry & product news, trends and resources. Click here.
podcasts
Mobility Management
  • HME Business
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • Contact Us
  • About Us

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise